OKYO Pharma Ltd Sustainability Reports

OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing therapeutics for inflammatory eye diseases and ocular pain. Its lead clinical product candidate is urcosimod (OK-101) for the treatment of dry eye disease and neuropathic corneal pain.

Sector: Manufacturing

Country: United Kingdom

Exchange: Nasdaq

LEI: 213800VVN5CB56Y15A05

FIGI: BBG015TS36P0

3 reports from 2018 to 2021

• OKYO Pharma Ltd 2021 Annual Report and Financial Statements
• OKYO Pharma Ltd 2020 Annual Report and Financial Statements
• OKYO Pharma Ltd 2018 Directors Report and Financial Statements